Clear Search

Showing 2 results for “Yap E”.

July 2025

Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Arthritis & Rheumatology 2025; 0:1–7 doi: 10.1002/art.43209

Exposure to voclosporin for a median of 18 months was not associated with onset or progression of nephrotoxicity based on evaluation of histologic compartments and vascular lesions. Rovin et al. characterised the impact of voclosporin on kidney histology in patients with LN who had protocolized repeat kidney biopsies in the AURORA clinical trials.

more…

December 2024

Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV and AURORA 1 studies and ALMS

Lupus Science & Medicine 2024;11:e001319 DOI: 10.1136/lupus-2024-001319

Dall’Era et al. conducted a propensity analysis to compare voclosporin-based triple immunosuppressive therapy with high-dose GC-based regimens for active LN. Voclosporin showed fewer AEs, improved safety, and significantly reduced proteinuria over six months, suggesting a superior risk-benefit profile for patients with lupus nephritis.

more…